Biopharmaceutical innovation and rare disease research by Vanda Pharmaceuticals

  • Parshwa Turakhiya
  • 27.05.2026
Vanda Pharmaceuticals secures orphan drug designation in Japan for Imsidolimab in generalized pustular psoriasis
Vanda Pharmaceuticals has announced that Japanese regulators have granted orphan drug designation to its investigational therapy Imsidolimab for the treatment of generalized pustular psoriasis. ...
  • Anastasiia Chabaniuk
  • 02.05.2026
NEREUS now available for online purchase as Vanda Pharmaceuticals expands access
Vanda Pharmaceuticals has announced the commercial availability of NEREUS, known generically as tradipitant, which can now be ordered directly by consumers in the U.S. The medication is positioned ...
  • Yulia Slavina
  • 20.03.2026
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing
Vanda Pharmaceuticals is calling on the U.S. Food and Drug Administration to take stronger measures to speed up the transition from animal testing to human-relevant methodologies. The company is ...